AbbVie has revealed positive data from a post-hoc analysis of the Phase III Measure Up 1 and Measure Up 2 clinical trials of RINVOQ (upadacitinib) in treating moderate-to-severe atopic dermatitis (AD).
The trials assessed 15mg or 30mg doses of upadacitinib compared to placebo to treat AD patients, particularly those with varying degrees of disease severity in the head and neck areas.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
These randomised, multicentre, double-blind, parallel-group, placebo-controlled studies assessed the efficacy and safety of RINVOQ in adults and adolescents aged 12 years or older who are systemic treatment candidates.
In the analysis, various treatment targets – such as attaining near complete skin clearance in the head and neck region (EASI Head & Neck score <1), near complete skin clearance (EASI 90), no to little itch (WP-NRS 0/1) and minimal or no impact on quality of life (DLQI 0/1) – were evaluated in patients treated with upadacitinib.
The post-hoc analysis findings indicated that a greater proportion of trial subjects treated with both doses of upadacitinib attained near-complete skin clearance in the head and neck region, reduced impact on quality of life, and minimal disease activity at week 16 versus placebo.
Minimal disease activity meant that the patients had near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataA selective and reversible JAK inhibitor, RINVOQ is under investigation for various immune-mediated inflammatory diseases.
Apart from AD, the asset is currently being analysed in Phase III trials for alopecia areata, giant cell arteritis, Takayasu arteritis, hidradenitis suppurativa, systemic lupus erythematosus, and vitiligo.
AbbVie immunology global medical affairs vice-president Andrew Anisfeld said: “Despite taking steps to manage their condition, many patients with atopic dermatitis continue to live with debilitating symptoms, especially in highly visible areas such as head and neck that can intensify one’s physical and emotional burden.
“These data contribute to our ongoing commitment to elevate the standard of care in atopic dermatitis so patients can strive for the best possible outcomes.”
In June, the company reported positive data from the Phase II PICCOLO trial of mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated high folate receptor-alpha (FRα)-positive platinum-sensitive ovarian cancer (PSOC) patients.
